| 1.17 0.04 (3.54%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.43 | 1-year : | 1.67 |
| Resists | First : | 1.23 | Second : | 1.43 |
| Pivot price | 1.14 |
|||
| Supports | First : | 1.1 | Second : | 1.01 |
| MAs | MA(5) : | 1.14 |
MA(20) : | 1.13 |
| MA(100) : | 1.14  |
MA(250) : | 1.29 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 53.2 |
D(3) : | 46.4 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 1.95 | Low : | 1.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PLRX ] has closed below upper band by 22.0%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.19 | 1.19 - 1.19 |
| Low: | 1.13 - 1.13 | 1.13 - 1.14 |
| Close: | 1.16 - 1.17 | 1.17 - 1.18 |
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Wed, 19 Aug 2026
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX) - The Globe and Mail
Wed, 19 Aug 2026
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation - simplywall.st
Sat, 15 Aug 2026
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support Zone - Value Stock Ideas - vinanet.vn
Tue, 11 Aug 2026
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Mon, 13 Jul 2026
Pliant Therapeutics adds two directors with oncology expertise - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 79.3 (%) |
| Shares Short | 2,770 (K) |
| Shares Short P.Month | 2,820 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|